Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 4;20(1):421–436. doi: 10.1002/alz.13447

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

ROC analysis of comorbid non‐ADNC positivity prediction in autopsy‐confirmed main study cohort of CU elderly individuals, individuals with MCI, and individuals with dementia due to AD. The full multidisciplinary model used harmonized ICV‐adjusted regional volumetric estimates from automated MUSE parcellation, demographics, number of APOE alleles (ε2 and ε4 separately), MMSE, CDR, and end‐of‐life ADNC status (Aβ positivity and tau positivity separately) as primary predictor variables. Reference classifiers were constructed to assess the added value of ADNC biomarkers together with MRI volumetrics. TDP‐43 positivity: none versus inclusions in amygdala, hippocampus, entorhinal/inferior temporal cortex, or neocortex. LBD positivity: none versus amygdala predominant, limbic (transitional), or neocortical (diffuse) LBD pathology. CAA positivity: none or mild versus moderate or severe CAA in Model 1; none versus mild, moderate, or severe CAA in Model 2.